Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab and High-Dose Chemotherapy in Ph-negative ALL
NCT04554485Phase 2Completed
- Sponsor
- Institute of Hematology and Blood Transfusion
- Start
- May 2019
- Primary completion
- Feb 2024
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of blinatumomab in acute lymphoblastic leukemia (ALL), sponsored by Institute of Hematology and Blood Transfusion. Started May 2019; status: completed.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT04554485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04554485.